New drug trial aims to ease pouch disorder symptoms

NCT ID NCT06864403

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 30 times

Summary

This study tests whether mirikizumab can reduce symptoms of chronic pouch inflammation in 25 adults. Participants receive the drug every 4 weeks for a year and track their symptoms. The goal is to see if it helps control the condition without needing ongoing antibiotics.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POUCHITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allegheny Health Network

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UCLA Vatche & Tamar Manoukian Division of Digestive Diseases

    RECRUITING

    Los Angeles, California, 90024, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27599-7080, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.